Drugs / ZSP1602
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03734913 | Jan 2019 → Jul 2021 | gastroesophageal junction adenocarcinoma, glioblastoma, medulloblastoma, skin basal cell carcinoma +1 | Guangdong Zhongsheng Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZSP1602 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03734913 ↗ |
| Route | Oral | “ZSP1602 capsules for oral administration” NCT03734913 ↗ |